Skip to main content
Premium Trial:

Request an Annual Quote

New Virus Linked to Outbreak in China

A new coronavirus appears to be behind the pneumonia outbreak occurring in China, Vox reports.

Dozens of people in central China, including the city of Wuhan, have fallen ill in recent weeks. According to the Wall Street Journal, there were 27 reported cases of viral pneumonia in the region by the end of December and that number has risen to 59 such cases by Sunday. It notes that the virus does not appear to be transmitted between people and instead it is thought that the affected individuals were exposed at a live animal market.

Officials in China have sequenced a sample from one patient to uncover a novel coronavirus that was then found in additional patients in Wuhan, the Journal reports. The World Health Organization cautions that this is a preliminary identification and that additional analysis is needed. 

Chinese officials were criticized following the SARS outbreak in the early 2000s — which was caused by another coronavirus — for not disclosing information quickly, Vox notes. That led, the Journal says, to changes to China's disease control program that are now being tested.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.